First-in-Human Study of EOS100850 in Patients With Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and
tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor
activity of EOS100850 as a Single Agent and in Combination with Pembrolizumab and/or
Chemotherapy in Participants with Advanced Cancers.